购物车 
-
Ala-Ala-Asn-PAB
- names：
Ala-Ala-Asn-PAB
- CAS号：
2149584-00-7
MDL Number： MFCD28898921 - MF(分子式)： C17H25N5O5 MW(分子量)： 379.41
- EINECS: Reaxys Number:
- Pubchem ID:118966102 Brand:BIOFOUNT
Ala-Ala-Asn-PAB(2149584-00-7)是抗体偶联药物 (ADCs) 的常用一种蛋白可降解 (cleavable) 的 ADC linker。
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM001016-500mg | 500mg | ¥ 0.00 | ¥ 0.00 | Backorder | ¥ 0.00 | |||
| YZM001016-100mg | 100mg | >97% | ¥ 0.00 | ¥ 0.00 | 2-3天 | ¥ 0.00 |
| 中文别名 | Ala-Ala-Asn-PAB(2149584-00-7); |
| 英文别名 | Ala-Ala-Asn-PAB(2149584-00-7);SCHEMBL17615149;HY-129360;CS-0105007; |
| CAS号 | 2149584-00-7 |
| SMILES | OCC1=CC=C(NC([C@H](CC(N)=O)NC([C@H](C)NC([C@@H](N)C)=O)=O)=O)C=C1 |
| Inchi | InChI=1S/C17H25N5O5/c1-9(18)15(25)20-10(2)16(26)22-13(7-14(19)24)17(27)21-12-5-3-11(8-23)4-6-12/h3-6,9-10,13,23H,7-8,18H2,1-2H3,(H2,19,24)(H,20,25)(H,21,27)(H,22,26)/t9-,10-,13-/m0/s1 |
| InchiKey | VPXFRPRRAXTBSH-KWBADKCTSA-N |
| 分子式 Formula | C17H25N5O5 |
| 分子量 Molecular Weight | 379.41 |
| 闪点 FP | 473.6±34.3 °C |
| 熔点 Melting point | No data available |
| 沸点 Boiling point | 859.5±65.0 °C at 760 mmHg |
| Polarizability极化度 | 39.0±0.5 10-24cm3 |
| 密度 Density | 1.3±0.1 g/cm3 |
| 蒸汽压 Vapor Pressure | 0.0±0.3 mmHg at 25°C |
| 溶解度Solubility | |
| 性状 | Solid |
| 储藏条件 Storage conditions | 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description. |
Ala-Ala-Asn-PAB(2149584-00-7)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:2149584-00-7试剂,2149584-00-7杂质,2149584-00-7合成,2149584-00-7密度,2149584-00-7旋光度,2149584-00-7溶解度,2149584-00-7闪点,2149584-00-7购买,
| 产品说明 | Ala-Ala-Asn-PAB(2149584-00-7)实验注是抗体偶联药物 (ADCs) 的常用一种蛋白可降解的ADC连接桥 |
| Introduction | Ala-Ala-Asn-PAB(2149584-00-7)实验注s a peptide cleavableADC linkerfor antibodyrug conjugates (ADCs). |
| Application1 | |
| Application2 | |
| Application3 |
Ala-Ala-Asn-PAB(2149584-00-7)药理学：
Ala-Ala-Asn-PAB(2149584-00-7)是抗体偶联药物 (ADCs) 的常用一种蛋白可降解 (cleavable) 的 ADC linker。
Ala-Ala-Asn-PAB(2149584-00-7)是抗体偶联药物 (ADCs) 的常用一种蛋白可降解 (cleavable) 的 ADC linker。
| 警示图 | |
| 危险性 | warning |
| 危险性警示 | Not available |
| 安全声明 | H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害 |
| 安全防护 | P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理 |
| 备注 | 实验过程中防止吸入、食入，做好安全防护 |
| Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 |
Ala-Ala-Asn-PAB(2149584-00-7)参考文献：
1、MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα
Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity Xin Cheng 1, Jing Li 2, Keigo Tanaka 3, Utpal Majumder 4, Andrew Z Milinichik 1, Arielle C Verdi 1, Christopher J Maddage 5, Katherine A Rybinski 5, Shawn Fernando 6, Danielle Fernando 6, Megan Kuc 6, Keiji Furuuchi 5, Frank Fang 2, Toshimitsu Uenaka 5, Luigi Grasso 7, Earl F Albone 8
Abstract Microtubule-targeting agents (MTA) have been investigated for many years as payloads for antibody-drug conjugates (ADC). In many cases, these ADCs have shown limited benefits due to lack of efficacy or significant toxicity, which has spurred continued investigation into novel MTA payloads for next-generation ADCs. In this study, we have developed ADCs using the MTA eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, as a payload. Eribulin ADCs demonstrated in vitro potency and specificity using various linkers and two different conjugation approaches. MORAb-202 is an investigational agent that consists of the humanized anti-human folate receptor alpha (FRA) antibody farletuzumab conjugated via reduced interchain disulfide bonds to maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl-eribulin at a drug-to-antibody ratio of 4.0. MORAb-202 displayed preferable biophysical properties and broad potency across a number of FRA-positive tumor cell lines as well as demonstrated improved specificity in vitro compared with farletuzumab conjugated with a number of other MTA payloads, including MMAE, MMAF, and the reducible maytansine linker-payload sulfo-SPDB-DM4. A single-dose administration of MORAb-202 in FRA-positive human tumor cell line xenograft and patient-derived tumor xenograft models elicited a robust and durable antitumor response. These data support further investigation of MORAb-202 as a potential new treatment modality for FRA-positive cancers, using the novel MTA eribulin as a payload.
1、MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα
Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity Xin Cheng 1, Jing Li 2, Keigo Tanaka 3, Utpal Majumder 4, Andrew Z Milinichik 1, Arielle C Verdi 1, Christopher J Maddage 5, Katherine A Rybinski 5, Shawn Fernando 6, Danielle Fernando 6, Megan Kuc 6, Keiji Furuuchi 5, Frank Fang 2, Toshimitsu Uenaka 5, Luigi Grasso 7, Earl F Albone 8
Abstract Microtubule-targeting agents (MTA) have been investigated for many years as payloads for antibody-drug conjugates (ADC). In many cases, these ADCs have shown limited benefits due to lack of efficacy or significant toxicity, which has spurred continued investigation into novel MTA payloads for next-generation ADCs. In this study, we have developed ADCs using the MTA eribulin, a derivative of the macrocyclic polyether natural product halichondrin B, as a payload. Eribulin ADCs demonstrated in vitro potency and specificity using various linkers and two different conjugation approaches. MORAb-202 is an investigational agent that consists of the humanized anti-human folate receptor alpha (FRA) antibody farletuzumab conjugated via reduced interchain disulfide bonds to maleimido-PEG2-valine-citrulline-p-aminobenzylcarbamyl-eribulin at a drug-to-antibody ratio of 4.0. MORAb-202 displayed preferable biophysical properties and broad potency across a number of FRA-positive tumor cell lines as well as demonstrated improved specificity in vitro compared with farletuzumab conjugated with a number of other MTA payloads, including MMAE, MMAF, and the reducible maytansine linker-payload sulfo-SPDB-DM4. A single-dose administration of MORAb-202 in FRA-positive human tumor cell line xenograft and patient-derived tumor xenograft models elicited a robust and durable antitumor response. These data support further investigation of MORAb-202 as a potential new treatment modality for FRA-positive cancers, using the novel MTA eribulin as a payload.
对不起，暂无产品评价！
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
怎么做细胞爬片免疫组化染色实验
细胞爬片免疫组化染色，是通过细胞爬片是让玻片浸在细胞培养基内，细胞在玻片上生长，主要用于组织学，免疫组织化学...
2020/7/20 22:04:33
提取病毒RNA的实验方法
提取病毒RNA方法分别有：异硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
各种微流控芯片键合方法的优缺点
微流控芯片键合：目前主要有激光焊接、热压键合、胶键合、超音波焊接，每种方法都有各自的优缺点。本文主要介绍聚酯...
2023/7/28 10:43:09
新一代微流控键合解决方案
微流控键合解决方案：微流控芯片制造的一个重要环节，也是最容易被忽视的--芯片键合。其中一个重要因素是：微流控...
2023/7/27 12:44:28
荧光素钾盐使用说明
D-荧光素钾盐（K+）设计用于体外和体内生物发光测定。D-荧光素的质量和纯度对于获得良好和可重复的结果至关重...
2023/7/20 11:05:11
如何选BSA（牛血清白蛋白）
如何选BSA（牛血清白蛋白）：牛血清白蛋白（BSA）有多种形式，如何选择适合自己的牛血清白蛋白（BSA）是一...
2023/2/14 13:09:18
牛血清白蛋白（BSA）常见问题
牛血清白蛋白（BSA）常见问题:牛血清白蛋白（BSA）在实验室中是通用的，可用于蛋白质印迹、细胞组织培养、P...
2022/10/19 9:39:51
pubmed使用方法(技巧)
pubmed使用方法(技巧)：PubMed是一个关于医学问题的学术文章和书籍的数据库。因为它是一份学术期刊，...
2022/10/18 18:06:07
BSA(牛血清白蛋白)
BSA(牛血清白蛋白):牛血清白蛋白（BSA）是一种球状蛋白质，牛血清白蛋白（BSA）是发现于牛血浆中的主要...
2022/10/18 16:48:12
冻干培养细菌的方法
冻干培养细菌的方法：冷冻干燥，也称为冻干或冷冻干燥，是在产品冷冻后除去水分并将其置于真空中的过程。这使得冰可...
2022/10/16 8:27:31
